Clinical trial · Interventional
Effect of Papaverine on Renal Artery Blood Flow Volume
Effect of Papaverine on Intraoperative Renal Artery Blood Flow Volume in Patients Undergoing Robot-assisted Partial Nephrectomy : a Randomized, Placebo-controlled Study
NCT04162834CI-TRIAL-00051310completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the effect of papaverine on renal artery blood flow after declamping of renal artery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Normal saline | Drug | — | UNRESOLVED |
| Papaverine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Papaverine group
- description
- Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.
- interventionNames
- Drug: Papaverine
- type
- ACTIVE_COMPARATOR
- label
- Normal saline group
- description
- Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
- interventionNames
- Drug: Normal saline
Primary outcomes (1)
- measure
- Renal artery blood flow
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 79 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with kidney cancer. * Patients undergoing robot assisted partial nephrectomy under general anesthesia * 20 years old ≤ age \<80 years old * Patients who voluntarily agreed to this clinical study * eGFR ≥ 60 ml / min / 1.73 m2 (Chronic Kidney Disease Epidemiology Patients with Collaboration) Exclusion Criteria: * The tumor ≥ 7 cm in size * Multiple renal mass * If the surgery plan is changed due to open * When surgery is performed together with other surgery * Multiple renal artery * Patients with hypersensitivity to papaverine * Patients with atrioventricular block * Pregnant and lactating women * Patients using levodopa * Refusal of patient
References
Publications (0)
Data not yet available
No reference posted for this study.